Premier Hb9210™ HbA1c Analyzer
Diabetes monitoring (HbA1c testing)
Approved/CommercialMarketed - IFCC Gold Classification 2026
Key Facts
Indication
Diabetes monitoring (HbA1c testing)
Phase
Approved/Commercial
Status
Marketed - IFCC Gold Classification 2026
Company
About Trinity Biotech
Trinity Biotech is a publicly-traded diagnostics company on a mission to provide high-quality clinical testing solutions globally. Recent key achievements include regaining compliance with NASDAQ listing requirements, securing the prestigious IFCC Gold Classification for 2026 for its Premier Hb9210™ HbA1c analyzer, and obtaining regulatory approval to commence offshored manufacturing for its flagship Uni-Gold™ HIV test. The company's core strategy revolves around transforming its financial performance through cost-structure optimization via manufacturing offshoring and outsourcing, while leveraging its established portfolio in hemoglobinopathies, infectious disease, and autoimmune diagnostics.
View full company profileTherapeutic Areas
Other Diabetes monitoring (HbA1c testing) Drugs
| Drug | Company | Phase |
|---|---|---|
| OneDraw A1C System | Drawbridge Health | Approved |